"There is no dose-response relationship in psychopharmacotherapy" vs "pharmacotherapy in psychiatry is based on ligand-receptor interaction": A unifying hypothesis and the need for plasma concentration based clinical trials

Psychopharmacology

Volumn 217, Issue 2, 2011, Pages 297-300

  Eggart, Vincent ^a   Hiemke, Christoph ^b   Zernig, Gerald ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FLUVOXAMINE; LIGAND; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG THERAPY; EXTRACELLULAR SPACE; HUMAN; INTERMETHOD COMPARISON; NOTE; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOPHARMACOTHERAPY; RECEIVER OPERATING CHARACTERISTIC; SEROTONIN SYNDROME; STEADY STATE;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; LIGANDS; MODELS, PSYCHOLOGICAL; PROTEIN BINDING; PSYCHOPHARMACOLOGY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 82955233695     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2319-z     Document Type: Note

References (16)

1. Anonymous (1985) Tricyclic antidepressants-blood level measurements and clinical outcome: an APA Task Force report. Task Force on the Use of Laboratory Tests in Psychiatry. Am J Psychiatry 142:155-162
2. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M (2005) Is dose escalation of antidepressants a rational strategy after a mediumdose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 255:387-400 (Pubitemid 43029828)
3. Baumann P, Hiemke C, Ulrich S, Gaertner I, Rao ML, Eckermann G, Gerlach M, Kuss HJ, Laux G, MuellerO, Erlinghausen B, Riederer P, Zernig G (2004) Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guidelines. Ther Drug Monit 26:1-4
4. Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF (1989) Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 25:71-79 (Pubitemid 19179164)
5. Gründer G, Fellows C, Janouschek H, Veselinovic T, Boy C, Brocheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rosch F, Schaefer WM, Vernaleken I (2008) Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 165:988-995
6. Hegerl U, Bottlender R, Gallinat J, Kuss HJ, Ackenheil M, Moller HJ (1998) The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neuroscience 248:96-103 (Pubitemid 28279551)
7. Kenakin TP (2006) A pharmacology primer. Theory, application, and methods. Elsevier, Amsterdam
8. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826-835 (Pubitemid 38625335)
9. Ostad E, Tadic A, Wagner S, Dragicevic A, Möller MJ, Boland J, Rao ML, Fric M, Laux G, Hiemke C (2011) Association between citalopram serum levels and clinical improvement of patients with major depression. J Clin Psychpharmacol 31: in press
10. Rasmussen BB, Brosen K (2000) Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 22:143-154 (Pubitemid 30196816)
11. Suzuki Y, Fukui N, Sawamura K, Sugai T, Watanabe J, Ono S, Inoue Y, Ozdemir V, Someya T (2008) Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression. J Clin Psychopharmacol: 325-8
12. Tanum L, Strand LP, Refsum H (2010) Serum concentrations of citalopram-dose-dependent variation in R- and S-enantiomer ratios. Pharmacopsychiatry 43:190-193
13. Tasker TC, Kaye CM, Zussman BD, Link CG (1989) Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatrica Scand Suppl 350:152-155 (Pubitemid 19236668)
14. Uhr M, Grauer MT, Holsboer F (2003) Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54:840-846 (Pubitemid 37205136)
15. Ulrich S, Wurthmann C, Brosz M, Meyer FP (1998) The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinetics 34:227-263 (Pubitemid 28112401)
16. Zernig G, Ahmed SH, Cardinal RN, Morgan D, Acquas E, Foltin RW, Vezina P, Negus SS, Crespo JA, Stockl P, Grubinger P, Madlung E, Haring C, Kurz M, Saria A (2007) Explaining the escalation of drug use in substance dependence: models and appropriate animal laboratory tests. Pharmacology 80:65-119 (Pubitemid 47230704)